Subscribe
shutterstock_1960556293_molly_woodward
Molly Woodward / Shutterstock.com
9 June 2022GenericsMuireann Bolger

Pfizer sues MSN Labs over Xeljanz generic

Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz (tofacitinib citrate), used to treat patients with arthritis.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pfizer drops Xeljanz patent suits
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
Americas
MSD sues Pfizer’s Wyeth over vaccine patents
14 January 2021   Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.
Big Pharma
Pharma company hit with racial discrimination lawsuit
20 September 2022   Pfizer’s ‘Breakthrough’ programme is aimed at Black, Latino and Native Americans | A healthcare membership organisation filed the complaint.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Pfizer drops Xeljanz patent suits
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
Americas
MSD sues Pfizer’s Wyeth over vaccine patents
14 January 2021   Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.
Big Pharma
Pharma company hit with racial discrimination lawsuit
20 September 2022   Pfizer’s ‘Breakthrough’ programme is aimed at Black, Latino and Native Americans | A healthcare membership organisation filed the complaint.

More on this story

Big Pharma
Pfizer drops Xeljanz patent suits
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
Americas
MSD sues Pfizer’s Wyeth over vaccine patents
14 January 2021   Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.
Big Pharma
Pharma company hit with racial discrimination lawsuit
20 September 2022   Pfizer’s ‘Breakthrough’ programme is aimed at Black, Latino and Native Americans | A healthcare membership organisation filed the complaint.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York